Home / Peptides

Cagrilintide

Shop Cagrilintide
Code ths10 applied at checkout

Also called: Cagrilintide UK & Lab UK, CagriSema (Semaglutide + Cagrilintide), Cagrilintide-Semaglutide Combination

By The Health Stacks Research TeamUpdated September 14, 2026

Cagrilintide is a special chemical that acts like a hormone called amylin found in the human body. It is made in a lab and is often grouped with other weight loss tools, but it works differently than many of them. Scientists study it to see how it helps people control how much they eat. It is mostly looked at by researchers who want to find new ways to help with weight problems. This chemical works by talking to the brain and the stomach.

It helps the stomach empty its food more slowly, which makes a person feel full for a longer time. It also works on the brain to stop the urge to eat. Because it affects both the stomach and the brain, it can lower the amount of food someone wants to eat. This is why it is studied for its ability to help control body weight. Right now, Cagrilintide is still being tested and is not a medicine that people can just get.

It is usually sold only for lab research and not for humans to use yet. Some studies show it might work well when mixed with other drugs, but we are still learning about it. There are some side effects, mostly feeling sick to the stomach. It is important to know that it is not approved for general use by health officials.

Research-stageEarly-stage — evidence so far is mostly cell, animal, or preliminary human studies. Not an approved medicine. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.

Benefits

What Cagrilintide Helps With

The benefits people report — backed by research.

Weight management (10)

Weight management 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 4 srcAppetite control 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcMechanism-based treatment for obesity 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcAppetite reduction 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Satiety induction 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonists lower risk for dementia, ischemic stroke, and all-cause mortality in T2D with obesity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Energy metabolism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite regulation via Amylin pathway 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Appetite Regulation 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Glycemic & metabolic (6)

Metabolic control 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcImprovement in beta-cell function 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significant HbA1c reduction in adults with type 2 diabetes inadequately controlled by diet and exercise 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Superior HbA1c reduction when combined versus semaglutide alone in patients on metformin 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Alternative for GLP-1 Intolerant Patients 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (3)

Treatment of Atypical Femur Fracture 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcEnergy metabolism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonists impact objective physical activity in adults 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Cagrilintide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

How People Use It

1 reported routine — each line links to the source it came from.

From published sources

Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.

SubQ

  • 2.4 mg each (Cagrilintide 2.4 mg + Semaglutide 2.4 mg) 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • Infection risk from impurities in unapproved animal-derived thyroid medicationsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →endocrinologyadvisor.com
  • Overtreatment or undertreatment from inconsistent thyroid hormone levelsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →endocrinologyadvisor.com
  • NauseaMildReported in 10 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources10Every claim links to the page it came from, and stronger sources rate higher. Full methodology →withpower.compeptidedosage.orgpeptidedeck.compeptidesexplorer.com+6
  • VomitingMildReported in 11 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources11Every claim links to the page it came from, and stronger sources rate higher. Full methodology →withpower.comwithpower.compeptidedosage.orgpeptidedeck.com+7
  • Gastrointestinal / Stomach-related side effectsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →withpower.com
  • Serious side effectsSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →withpower.com

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Cagrilintide

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Cagrilintide
Code ths10 applied at checkout

Timeline

History & Milestones

Key moments in Cagrilintide’s research and regulatory timeline — sourced and dated.

  1. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of ObesityPublicationJan 1, 2024
    Related:Cagrilintide
    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

News

Latest on Cagrilintide

Dated, sourced reporting that mentions Cagrilintide.

ClinicalJul 29, 2026

Weight loss: New drug CagriSema leads to 14% weight loss in trial

Novo Nordisk's experimental combination therapy CagriSema demonstrated superior weight loss and blood sugar control compared to semaglutide alone in a Phase 3 trial. The drug combines the GLP-1 agonist semaglutide with cagrilintide, an amylin receptor agonist, resulting in a 14.2% reduction in body weight over 68 weeks. These results suggest a potential new standard for treating type 2 diabetes and obesity.

72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
SafetyAug 13, 2025

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis | International Journal of Obesity

A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.

72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →

Wondering how Cagrilintide pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.